Loading…

Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes. Data from the Swedish Heart Failure and Swedish National Diabetes Registries

To assess use and associations with outcomes of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in a real-world population with heart failure (HF) and type 2 diabetes (T2DM). The Swedish HF Registry was linked with the National Diabetes Registry and other national registries. Independent predic...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal. Cardiovascular pharmacotherapy 2024, Vol.10 (4), p.296-306
Main Authors: Wallner, Markus, Biber, Mattia Emanuele, Stolfo, Davide, Sinagra, Gianfranco, Benson, Lina, Dahlström, Ulf, Gudbjörnsdottir, Soffia, Cosentino, Francesco, Mol, Peter G M, Rosano, Giuseppe M C, Butler, Javed, Metra, Marco, Lund, Lars H, Ferrannini, Giulia, Savarese, Gianluigi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess use and associations with outcomes of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in a real-world population with heart failure (HF) and type 2 diabetes (T2DM). The Swedish HF Registry was linked with the National Diabetes Registry and other national registries. Independent predictors of GLP-1 RA use were assessed by multivariable logistic regressions, and associations with outcomes by Cox regressions in a 1:1 propensity score-matched cohort. Of 8188 patients enrolled in 2017-2021, 9% received a GLP-1 RA. Independent predictors of GLP-1 RA use were age
ISSN:2055-6837
2055-6845
2055-6845
DOI:10.1093/ehjcvp/pvae026